You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 42 No. 12, December 1985 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

High-Dose Intravenous Methylprednisolone in Myasthenia Gravis

Edward Arsura, MD; Norman G. Brunner, MD; Tatsuji Namba, MD; David Grob, MD

Arch Neurol. 1985;42(12):1149-1153.


Abstract

• Corticosteroids have been useful in the management of myasthenia gravis (MG), but their efficacy has been limited by the slow onset of improvement, initial worsening of MG, refractoriness of some patients, and side effects of large daily doses. High-dose intravenous methylprednisolone pulses have been reported to produce rapid improvement in several immunologic disorders. In this study we administered 2 g of methylprednisolone intravenously every five days to 15 consecutive patients who had exacerbation of generalized MG. Satisfactory improvement occurred in ten of 15 patients after two courses and in two of five patients after a third course. Onset of improvement began a mean (±SD) of 3 ± 1.1 days after the first infusion, 2.1 ± 1 days after the second, and 2.4 ± 1 days after the third, and reached its maximum level 8.9 ± 6.1 days after the last infusion. A decrease in strength occurred in three patients 1.43 ± 1.30 days after each infusion, was not marked, and lasted three days, following which improvement generally occurred. Side effects were minimal. After improvement, a daily dose of prednisone (30 mg) was used to maintain improvement. Use of pulse therapy at five-day intervals for the management of severe MG seems to have an advantage in that it produces less initial worsening and more rapid improvement in MG, enabling smaller daily maintenance doses to be employed, with fewer side effects.



Author Affiliations

From the Department of Medicine, Maimonides Medical Center, Brooklyn, NY.


Footnotes

Accepted for publication March 18, 1985.

Reprint requests to Maimonides Medical Center, 4802 Tenth Ave, Brooklyn, NY 11219 (Dr Arsura).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Review: Progress in the treatment of myasthenia gravis
Gold et al.
Therapeutic Advances in Neurological Disorders 2008;1:99-114.
ABSTRACT  

High-Dose Intravenous Immunoglobulin in the Management of Myasthenia Gravis
Arsura et al.
Arch Intern Med 1986;146:1365-1368.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1985 American Medical Association. All Rights Reserved.